Trade

with

Geron Corp
(NASDAQ: GERN)
AdChoices
2.15
-0.01
-0.46%
After Hours :
2.15
0.00
0.00%

Open

2.17

Previous Close

2.16

Volume (Avg)

1.05M (2.06M)

Day's Range

2.14-2.20

52Wk Range

1.39-7.79

Market Cap.

337.30M

Dividend Rate ( Yield )

-

Beta

1.90

Shares Outstanding

156.88M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.28M

    • Net Income

    • -38.38M

    • Market Cap.

    • 337.30M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -2,842.67

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.90

    • Forward P/E

    • -11.25

    • Price/Sales

    • 243.90

    • Price/Book Value

    • 2.34

    • Price/Cash flow

    • -11.07

      • EBITDA

      • -38.00M

      • Return on Capital %

      • -31.16

      • Return on Equity %

      • -32.59

      • Return on Assets %

      • -31.16

      • Book Value/Share

      • 0.92

      • Shares Outstanding

      • 156.88M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 204.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -14.47

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -2,842.67

            • 39.38

            • Net Profit Margin

            • -2,842.67

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -3,342.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 29.98

              • 2.92

              • Quick Ratio

              • 29.77

              • 2.35

              • Interest Coverage

              • -549.94

              • 38.02

              • Leverage Ratio

              • 1.03

              • 2.21

              • Book Value/Share

              • 0.92

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.67

                • 277.78

                • P/E Ratio 5-Year High

                • -29.56

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.45

                • 124.82

                • Price/Sales Ratio

                • 243.90

                • 9.35

                • Price/Book Value

                • 2.34

                • 8.50

                • Price/Cash Flow Ratio

                • -11.07

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -32.59

                    (-54.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -31.16

                    (-48.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -32.53

                    (-54.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -38.96M
                  Operating Margin
                  -3,036.48
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -11.07
                  Ownership

                  Institutional Ownership

                  51.25%

                  Top 10 Institutions

                  40.16%

                  Mutual Fund Ownership

                  33.19%

                  Float

                  86.92%

                  5% / Insider Ownership

                  3.16%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    15,693,826

                  • 0.00

                  • 10.00

                  • SPDR® S&P Biotech ETF

                  •  

                    7,197,742

                  • 3.60

                  • 5.00

                  • British & American Investment Trust PLC

                  •  

                    3,480,242

                  • 0.11

                  • 2.82

                  • Fidelity® Puritan® Fund

                  •  

                    3,141,000

                  • 0.00

                  • 2.00

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    2,782,517

                  • 0.00

                  • 1.77

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,577,302

                  • 0.00

                  • 1.64

                  • iShares Russell 2000 (AU)

                  •  

                    2,453,429

                  • -1.02

                  • 1.70

                  • iShares Nasdaq Biotechnology

                  •  

                    2,082,582

                  • -0.69

                  • 1.45

                  • Vanguard Extended Market Index Fund

                  •  

                    1,525,852

                  • 0.39

                  • 0.97

                  • Fidelity Advisor® Growth Opportunities

                  •  

                    1,222,800

                  • 0.00

                  • 0.78

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    23,540,743

                  • +1.37%

                  • 15.88

                  • State Street Corp

                  •  

                    7,577,092

                  • -39.68%

                  • 5.11

                  • BlackRock Fund Advisors

                  •  

                    5,789,150

                  • -7.44%

                  • 3.91

                  • Camber Capital Management LLC

                  •  

                    5,000,000

                  • +6.38%

                  • 3.37

                  • Vanguard Group, Inc.

                  •  

                    4,773,645

                  • +2.32%

                  • 3.22

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    3,548,124

                  • +16.17%

                  • 2.39

                  • British & American Investment Trust PLC

                  •  

                    3,480,242

                  • +0.11%

                  • 2.82

                  • Redmile Group, LLC

                  •  

                    2,051,312

                  • -3.13%

                  • 1.38

                  • Northern Trust Investments, N.A.

                  •  

                    1,743,202

                  • -9.93%

                  • 1.18

                  • Adage Capital Partners Gp LLC

                  •  

                    1,335,000

                  • -24.79%

                  • 0.90

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in t...morehe segment of the discovery and development of therapeutic products for oncology. It owns worldwide commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and internationa...morel laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.lessless

                  Key People

                  Dr. John A. Scarlett,M.D.

                  CEO/Director/President

                  Dr. Hoyoung Huh,M.D.,PhD

                  Chairman of the Board/Director

                  Ms. Olivia K. Bloom

                  CFO/Chief Accounting Officer/Executive VP, Divisional/Treasurer

                  Melissa A. Kelly Behrs

                  Executive VP, Divisional

                  Craig C. Parker

                  Executive VP, Divisional

                  • Geron Corp

                  • 149 Commonwealth Drive

                  • Menlo Park, CA 94025

                  • USA.Map

                  • Phone: +1 650 473-7700

                  • Fax: +1 650 473-7750

                  • geron.com

                  Incorporated

                  1990

                  Employees

                  46

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: